Back
Genesis Energy LP 10K Form
Sell
30
GEL
Genesis Energy LP
Last Price:
$10.06
Seasonality Move:
5.55%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-02 | 10Q | GEL/Genesis Energy LP Quarterly |
2023-08-03 | 10Q | GEL/Genesis Energy LP Quarterly |
2023-05-04 | 10Q | GEL/Genesis Energy LP Quarterly |
2022-10-27 | 10Q | GEL/Genesis Energy LP Quarterly |
2022-08-02 | 10Q | GEL/Genesis Energy LP Quarterly |
2022-05-04 | 10Q | GEL/Genesis Energy LP Quarterly |
Receive GEL News And Ratings
See the #1 stock for the next 7 days that we like better than GEL
GEL Financial Statistics
Sales & Book Value
Annual Sales: | $3.2B |
---|---|
Cash Flow: | $-32.3M |
Price / Cash Flow: | 0 |
Annual Sales: | $9.74 |
Price / Book: | 1.06 |
Profitability
EPS (TTM): | -0.74000 |
---|---|
Net Income (TTM): | $-2.6M |
Gross Margin: | $395.2M |
Return on Equity: | -0.16% |
Return on Assets: | -0.04% |
Genesis Energy LP Earnings Forecast
Key Genesis Energy LP Financial Ratios
-
The Gross Profit Margin over the past 28 years for GEL is 12.44%.
-
The Selling, General & Administrative Expenses for GEL have been equal to 2.07% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 199.73% of Operating Income.
-
The Net Earning history of GEL is 3.71% of Total Revenues.
-
Per Share Earnings over the last 28 years have been positive in 14 years.
Genesis Energy LP Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Oil, Gas & Consumable Fuels |
Sector: | Energy |
Current Symbol: | GEL |
CUSIP: | 371927 |
Website: | genesisenergy.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 1.03 |
Quick Ratio: | 0.85 |
Price-to-Earnings
Trailing P/E Ratio: | 47.05 |
---|---|
Forward P/E Ratio: | 0 |
GEL Technical Analysis vs Fundamental Analysis
Sell
30
Genesis Energy LP (GEL)
is a Sell
Is Genesis Energy LP a Buy or a Sell?
-
Genesis Energy LP stock is rated a SellThe current Genesis Energy LP [GEL] share price is $10.09. The Score for GEL is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.